VIP
VIP (Vasoactive Intestinal Peptide)
A 28-amino acid neuropeptide with potent anti-inflammatory, immune-modulating, and bronchodilatory properties. Used in CIRS protocols.
VIP is not approved by the FDA for human use. It is sold strictly for research purposes only and is not intended for human consumption, diagnosis, treatment, or prevention of any disease or condition. Purchase and use is entirely at your own risk.
Sourcing for research purposes?
View at Ascension Peptides →What it is
Vasoactive Intestinal Peptide (VIP) is a naturally occurring 28-amino acid neuropeptide found throughout the central and peripheral nervous systems, gut, and lungs. It was first isolated from pig intestine in 1970.
Its biological roles span immune regulation, vasodilation, bronchodilation, and circadian rhythm entrainment. In clinical practice, it has gained significant attention through Dr. Ritchie Shoemaker's CIRS (Chronic Inflammatory Response Syndrome) protocols, where intranasal VIP is used as a late-stage treatment for biotoxin illness.
What research shows
- Anti-inflammatory — suppresses pro-inflammatory cytokines (TNF-α, IL-6, IL-12)
- Bronchodilation — research in pulmonary arterial hypertension and asthma
- Circadian rhythm regulation and sleep quality improvement
- Immune modulation — promotes regulatory T-cell activity
- CIRS protocol data showing TGF-beta and other biomarker normalization
What remains unknown
- Long-term safety profile with chronic intranasal use
- Efficacy outside of CIRS/biotoxin illness context in controlled trials
- Optimal dosing across different indications
- Extent to which intranasal delivery achieves meaningful CNS concentrations
Administration basics
Common use cases
CIRS (biotoxin illness) treatment, immune modulation, anti-inflammatory protocols, pulmonary conditions.
Half-life
~1–2 minutes in plasma. CNS effects via intranasal are longer-acting.
Administration
Intranasal is primary route in CIRS protocols. IV use in pulmonary research.
Source this compound
Looking for VIP?
Ascension Peptides is a third-party research compound vendor. We link to them as an affiliate — if you purchase through our link we may earn a commission at no cost to you. All compounds are sold for research purposes only and are not intended for human use.
View at Ascension PeptidesResearch Protocols & Common Usage
Doses used in research
- Research has used 50–100mcg intranasally
- CIRS community protocols commonly report 50mcg intranasally twice daily
Administration routes studied
Typical protocol duration
CIRS protocols have used VIP over several weeks to months. Research protocols vary by indication.
Common stacking protocols
- VIP is typically used as part of comprehensive CIRS treatment protocols rather than general peptide stacking
Contraindications & combinations to avoid
- Hypotension — VIP is a potent vasodilator; should not be combined with blood pressure lowering medications without monitoring
- VIP should ideally be used only under physician supervision for CIRS protocols
Dosing information reflects doses used in published research and commonly reported community protocols only. This is not a personal recommendation. These compounds are not FDA-approved for human use in the contexts described. Consult a qualified healthcare provider before starting any protocol.
Considering stacking?
See the stacking guide for common combinations with VIP and what to avoid.
Track your VIP protocol
Log your experience, track outcomes over time, and get AI-powered interpretation of your results after 14 days of data. Private, $14.99/month.
Start trackingGet research updates
We'll notify you when we update the VIP page or publish related research.
More in the library
Community Reviews
Reviews reflect individual user experiences with research compounds and are not medical advice. Results vary. These compounds are not FDA approved for human use. Peptelligent does not verify reported experiences.
Write a Review
No reviews yet. Be the first to share your experience.